Tirofiban detailed information

Revision as of 15:33, 6 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +))
Jump to navigation Jump to search
Tirofiban detailed information
Clinical data
Routes of
administration
Exclusively intravenous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailabilityn/a (IV only)
Protein binding65%
Elimination half-life2 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H36N2O5S
Molar mass440.598 g/mol

WikiDoc Resources for Tirofiban detailed information

Articles

Most recent articles on Tirofiban detailed information

Most cited articles on Tirofiban detailed information

Review articles on Tirofiban detailed information

Articles on Tirofiban detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tirofiban detailed information

Images of Tirofiban detailed information

Photos of Tirofiban detailed information

Podcasts & MP3s on Tirofiban detailed information

Videos on Tirofiban detailed information

Evidence Based Medicine

Cochrane Collaboration on Tirofiban detailed information

Bandolier on Tirofiban detailed information

TRIP on Tirofiban detailed information

Clinical Trials

Ongoing Trials on Tirofiban detailed information at Clinical Trials.gov

Trial results on Tirofiban detailed information

Clinical Trials on Tirofiban detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tirofiban detailed information

NICE Guidance on Tirofiban detailed information

NHS PRODIGY Guidance

FDA on Tirofiban detailed information

CDC on Tirofiban detailed information

Books

Books on Tirofiban detailed information

News

Tirofiban detailed information in the news

Be alerted to news on Tirofiban detailed information

News trends on Tirofiban detailed information

Commentary

Blogs on Tirofiban detailed information

Definitions

Definitions of Tirofiban detailed information

Patient Resources / Community

Patient resources on Tirofiban detailed information

Discussion groups on Tirofiban detailed information

Patient Handouts on Tirofiban detailed information

Directions to Hospitals Treating Tirofiban detailed information

Risk calculators and risk factors for Tirofiban detailed information

Healthcare Provider Resources

Symptoms of Tirofiban detailed information

Causes & Risk Factors for Tirofiban detailed information

Diagnostic studies for Tirofiban detailed information

Treatment of Tirofiban detailed information

Continuing Medical Education (CME)

CME Programs on Tirofiban detailed information

International

Tirofiban detailed information en Espanol

Tirofiban detailed information en Francais

Business

Tirofiban detailed information in the Marketplace

Patents on Tirofiban detailed information

Experimental / Informatics

List of terms related to Tirofiban detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]


Tirofiban (INN, trade name Aggrastat®) is an anticoagulant drug. It belongs to a class of anticoagulants named glycoprotein IIb/IIIa inhibitors.

Basic chemical and pharmacological information

Tirofiban is a synthetic, nonpeptide inhibitor acting at glycoprotein-(GP)-receptors, type IIb/IIIa, in human thrombocytes. It therefore constitutes an anticoagulant, specifically an inhibitor of thrombocyte aggregation.

The drug is marketed in many countries under the brand name Aggrastat® by either Merck Sharp & Dohme or Medicure Pharma.

It is sold in parenteral dosage forms intended and readily constituted for IV administration containing 5 mg or 12.5 mg, respectively.

Tirofiban has a rapid onset and short duration of action after proper IV administration. Coagulation parameters turn to normal 4 to 8 hours after the drug is withdrawn.

Indications

Tirofiban in combination with heparin and aspirin is indicated in the management of patients with unstable angina or non-Q-wave myocardial infarction, including patients who may subsequently undergo percutaneous transluminal coronary angioplasty (PTCA), to decrease the rate of refractory ischemic conditions, new myocardial infarction and death.

Contraindications and precautions

Tirofiban is containdicated in patients with:

Cautions

Tirofiban should be used with caution in the following clinical situations:

Use in pregnancy

Tirofiban has been demonstrated to cross the placenta in pregnant rats and rabbits. Although the doses employeed in these studies were a multiple of those used in human beings no adverse effects on the offspring in both animals have been seen. However, there are no adequate and well controlled studies in pregnant women. Therefore, tirofiban should be used during pregnancy only if clearly indicated.

Nursing mothers: It is not known whether tirofiban is excreted in human milk. However, significant levels of tirofiban are excreted in rat milk. Therefore, nursing should be discontinued during the period of drug administration and the milk discarded. Nursing may resume 24 hours after cessation of treatment with tirofiban.

Pediatric use

Safety and effectiveness in children have not been established.

Other precautions and laboratory exams

The activated partial thromboplastin time (aPTT) is the most reliable coagulation parameter and should be obtained regularly during treatment, particular if a bleeding episode occurs that may be assiociated to tirofiban therapy. Other important hematological parameters are platelet count, clotting time, hematocrit and hemoglobin. Proper technique regarding artery site access for sheath placement and removal of sheath should be followed. Arterial sheaths should be removed when the patient's activated clotting time is < 180 sec. or 2 to 6 hours following withdrawal of heparin.

Side effects

The following side effects were noted under treatment with tirofiban and heparin (and aspirin, if tolerated). Other drugs were used as necessary.

The major adverse effect is bleeding on local sites of clinical intervention and systemically (regarding parts of the body or the whole body system). Major bleeding has occurred in 1.4 % of patients and minor bleeding in 10.5 %. Transfusions were required to terminate bleeding and to improve bleeding-related anemia in 4.0 % of all patients. Geriatric patients have experienced more bleeding episodes than younger, women more than man.

Thrombocytopenia was more often seen in the tirofiban + heparin group (1.5 %) than in the heparin control group (0.8 %). This adverse effect was usually readily reversible within days.

Positive fecal and urine hemoglobin tests have also been reported.

Post-marketing events have been the occurrence of intracranial bleeding, retroperitoneal bleeding, pulmonary hemorrhage and spinal-epidural hematoma. Fatal bleedings have been reported rarely.

Sometimes, thrombocytopenia was associated with chills, low-grade fever or bleeding complications (see above).

Cases of hypersenitivity including acute anaphylaxis have been seen.

Interactions

The concomitant application of warfarin or other oral anticoagulants may increase the risk of serious bleeding events. The decision whether maintenance therapy with these drugs should be discontinued during tirofiban treatment has to be made by the responsible clinician.

Dosage regime

Tirofiban is initially given as rapid intravenous infusion at a rate of 0.4 µg/kg and minute for 30 minutes. Upon completion of the initial infusion, the rate is decreased to 0.1 µg/kg and minute delivered as continuous infusion.

Duration of therapy

Patients who do not show any signs of recurrent ischemic symptoms and do not undergo angiography and angioplasty should be treated for at least 48 hours.

Patients proceeding into angiography and angioplasty should continue throughout both procedures and for at least 12 hours, and not more than 24 hours after angioplasty. Once a patient is clinically stable and no further coronary intervention is planned by the treating physician, the infusion should be discontinued.

Summary of trial results

In the multicenter, randomized, parallel, double-blind PRISM-PLUS trial component endpoints and a composite endpoint were defined for periods of 7 days, 30 days, and 6 months, respectively.

For the 7 days period the following results were obtained:

  • Myocardial infarction and death: Risk reduction for tirofiban/heparin compared with heparin alone: 42.8 %.
  • Myocardial infarction: Risk reduction for tirofiban/heparin compared with heparin alone: 46.6 %.
  • Death : No significant difference.
  • Refractory ischemia: Risk reduction for tirofiban/heparin compared with heparin alone: 29.6 %.
  • Composite endpoint: Risk reduction for tirofiban/heparin compared with heparin alone: 31.6 %.

All results for the 7 days period were statistically highly significant. At 30 days and 6 months the benefits of tirofiban/heparin remained statistically significant, although the differences to the control group were shrinking.

References

  • AHFS Database Online
  • Arzneimittel Datenbank (in German)

External links



de:Tirofiban


Template:WikiDoc Sources